In a bold move to tackle high prescription drug costs, President Donald J. Trump has directly reached out to major pharmaceutical companies, urging them to reduce prices in the US to match those offered in other developed nations. The Most-Favored-Nation (MFN) initiative, resurrected from previous challenges, aims to address the significant price differences Americans face, potentially decreasing drug costs by up to 59%.
With the issuance of an executive order titled ‘Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,’ Trump’s administration is pushing for substantial price reductions. The revived MFN policy has already caused a stir in the pharmaceutical market, leading to a drop in stock prices and raising concerns among investors. Despite the industry’s apprehension, the MFN order’s ultimate objective is clear: to bring down drug prices for American consumers in line with international standards, covering all brand-name medications without generic or biosimilar alternatives.
Read more on ajmc.com